3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Lung Cancer -

Cell Therapeutics lung cancer drug helps women

Lung CancerSep 27, 05

Cell Therapeutics Inc. on Tuesday said a mid-stage trial of it experimental lung cancer drug showed a significant survival benefit for women, sending its shares soaring more than 40 percent.

In the recently completed study, Cell Therapeutics said the 35 women with advanced non-small cell lung cancer who received its Xyotax plus the chemotherapy carboplatin had a 36 percent probability of living at least one year.

The was a statistically significant survival benefit over both the men in the study and those receiving just chemotherapy, the Seattle-based biotechnology company said at a presentation in New York.

Only 16 percent of the 39 men receiving the same regimen survived the deadly, difficult-to-treat disease for at least one year.

“To the best of our knowledge this is the first time a drug therapy for advanced lung cancer has consistently demonstrated such a strong survival advantage for women compared to men or compared to women randomized to treatment with standard chemotherapy,” the company’s chief medical officer, Jack Singer, said in a statement.

The company had previously reported that women treated with Xyotax survived significantly longer than women treated with the standard chemotherapy.

Shares of Cell Therapeutics were up 92 cents, or 43 percent, to $3.04 on Nasdaq, where they were the day’s highest percentage gainer.

Print Version
comments powered by Disqus

  Profiling approach to enable right lung cancer treatment match
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Moffitt Cancer Center Researchers Find Potential New Therapeutic Target for Treating Non-Small Cell Lung Cancer
  Genome-wide scan maps mutations in deadly lung cancers; reveals embryonic gene link
  Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
  Lung Cancer Culprit Could Offer Target for Therapy
  Testing lung tumors tailors drug treatments
  In Battle Against Lung Cancer, Investigators Eye Oncolytic Virus Therapy
  Men who eat soy may have lower lung cancer risk
  Lung Cancer Conference Leaders Honor Paul A. Bunn Jr., M.D.
  A new mouse could help understand how some lung cancer cells evade drug treatment
  Tiny RNA has big impact on lung cancer tumors


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site